Mesoblast Ltd (nasdaq:MESO) Share Price

Company Profile

Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUS
T: +61 396396036
E: [email protected]
https://www.mesoblast.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108

Recommended

Fear outweighs fundamentals as ASX share reaffirms outlook.

Nathan Zaia | 29 October 2026

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,025.40	12.80	0.14%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	23,317.82	359.17	1.56%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	63,290.11	1,369.36	-2.12%
NZX 50 Index	13,797.00	86.83	0.63%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,908.10	16.30	0.18%
SSE Composite Index	3,599.02	52.42	-1.44%